OPCM
FATE icon

Osborne Partners Capital Management’s Fate Therapeutics FATE Stock Holding History

Osborne Partners Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$12.6K – 203
2025
Q3 		$12.6K Buy
+10,000
New +$10.8K ﹤0.01% 206

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Osborne Partners Capital Management's FATE Position: Q4 2025 in Review

Osborne Partners Capital Management sold out of Fate Therapeutics (FATE) in Q4 2025, closing a stake of 10,000 shares — an estimated $12.6K sold.

Osborne Partners Capital Management first reported a position in FATE in Q3 2025 and held it in 1 quarter. The position peaked at $12.6K in Q3 2025. 146 funds tracked by Wall St. Rank hold FATE as of Q4 2025.

  • Osborne Partners Capital Management reported no remaining Fate Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Osborne Partners Capital Management sold 10,000 Fate Therapeutics shares in Q4 2025, an estimated $12.6K.
  • Osborne Partners Capital Management first reported a position in Fate Therapeutics in Q3 2025 and held it in 1 quarter.
  • Osborne Partners Capital Management's Fate Therapeutics position peaked at $12.6K in Q3 2025.
  • 146 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2025.

Based on Osborne Partners Capital Management's 13F filing for Q4 2025, filed 27 Jan 2026.